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Epidemiology of esophageal cancer
Esophageal cancer (EC) is the eighth common cancer worldwide 
causing over 400,000 deaths in 2008.1 It is responsible for about 
5.4% of all cancer-related deaths and was reported as the sixth 
most common cause of death from cancer.1 Considerable varia-
tions were reported for incidence of EC between different parts 
of the world. A geographic area extending from northern Iran to 
north-central China (Asian belt of EC) was considered as high- risk 
area for EC.2–4 Areas with intermediate risk of EC include South-
east Africa and parts of South America.3 Other parts of the world 
including the USA were reported as low-risk ones.1 EC is more 
common in men and more than 80% of cases occur in developing 
countries.1 Squamous cell carcinoma (SCC) and adenocarcinoma 
are the most common types of EC.2,5 Reports in the 1960s sug-
gested that the morphologic diagnosis in about 90% of EC cases 
were esophageal SCC (ESCC).3 Although recent studies showed 
an increase in esophageal adenocarcinoma and a decrease in ESCC 
in the Western countries,6–8 other reports from developing world 
including Iran suggested that ESCC still comprises more than 90% 
of EC cases.9,10 So, ESCC remains the most common type of EC 
in the developing world and an important health problem in high- 
risk areas.11
 Pathogenesis and etiology of ESCC
ESCC typically occurs by progression from dysplastic lesions 
within the normal squamous epithelium of the esophagus (Figure 
1).3 Esophageal squamous dysplasia (ESD) has been suggested 
as the only clinically important premalignant precursor lesion for 
ESCC.12,13(6'VDUHFODVVL¿HGLQWRWZRJURXSV7KH¿UVWLVORZ
grade dysplasia, which includes mild and moderate dysplasia. The 
second is high-grade dysplasia, which includes severe dysplasia.3 
Over months to years ESDs grow into tumor mass (ESCC).14  
Various factors may increase the risk of ESCC.15 These factors 
affect on the process of ESD development and its progression 
into ESCC. Genetic susceptibility was suggested to play a role in 
pathogenesis of ESCC.16,17 Relationships between some environ-
mental factors and the risk of ESCC were reported.18,19 Patients’ 
characteristics including alcohol drinking,20 tobacco smoking,20,21 
opium consumption,21 nass chewing,21 hot tea consumption,22 mate 
drinking,23 low intake of fruits and vegetables,24 low socioeconom-
ic status,25 and tooth loss26 may play role in development of ESCC. 
So, ESCC is a complex and multifactorial disease.
Prognosis of ESCC
Esophageal wall does not have true serosal layer. This makes 
ESCC a progressive cancer with relatively rapid invasion into 
neighboring structures.27 Most of ESCC cases present in late stag-
es, resulting in delayed diagnosis of the disease. Consequently, 
SURJQRVLVLVSRRULQWKHVHSDWLHQWV7KHRYHUDOO¿YH\HDUVXUYLYDO
of ESCC patients was reported as low as 9%.14 But, if the disease 
is detected in early stages, the survival rates will be considerably 
improved. Results of a study on 230 EC cases suggested that the 
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(QGRVFRSLF6FUHHQLQJIRU(6&&
¿YH\HDUVXUYLYDOUDWHLQSDWLHQWVZLWKPXFRVDOFDQFHUZDV
higher than those with submucosal cancer (64%).28 Wang, et al. 
UHSRUWHG¿YH\HDUVXUYLYDOUDWHVRIDQGLQHDUO\VWDJHV
of EC cases with esophagectomy and endoscopic mucosectomy, 
respectively.29,QDQRWKHUVWXG\IURP-DSDQWKH¿YH\HDUVXUYLYDO
rates in EC with stages 0, I, and IIA-IVB were 83%, 47%, and 
0%, respectively.30 Generally, the survival rate of EC was higher 
in high-income countries31,32 than low- and middle- income coun-
tries.33,34 
Detecting ESCC in earlier stages will decrease the costs, inci-
dence, mortality, and consequently the burden of the disease.35 Liu, 
et al. and Yang J, et al. showed that detecting and treating EC pa-
tients in early stages will result in a considerable reduction in costs 
DQGLQFUHDVHLQEHQH¿WV36,37 Regarding the results of a study from 
Italy, lymph node metastasis did not occur in patients with lesions 
restricted to esophageal mucosa including ESDs and intraepithelial 
neoplasia (carcinoma in situ).38 After invasion to submucosa, the 
rate of lymph node metastasis will increase dramatically. So, it is 
important to detect and control the disease in earlier stages. Detec-
tion and treatment of mucosal lesions will result in the best progno-
sis. Detecting these lesions should be considered as the main aim 
in early ESCC detection programs.
     
Controlling programs for ESCC
Appropriate treatment modality is usually selected for ESCC pa-
tients according to the stage of tumor.3 Mucosal lesions including 
ESDs and carcinoma in situ are treated by endoscopic mucosal 
resection (EMR), while the therapeutic options in localized ESCC 
include surgical resection, radiotherapy, and chemotherapy.3 Pa-
tients with advanced stage of ESCC may be treated by endoscopic 
palliative therapies such as laser therapy, argon plasma coagula-
tion, esophageal dilation, and esophageal stent replacement.3 De-
spite availability of a wide range of therapeutic options, preven-
tion is the most effective strategy to control ESCC. Primary and 
secondary preventive methods may be considered for ESCC. In 
primary prevention, we try to prevent the initiation of the ESD 
(Figure 1). But ESD is a multifactorial condition and it may not 
be possible to identify and eliminate all of its risk factors. The aim 
of secondary prevention is to detect and eliminate ESD, prevent-
ing its progression into advanced stages. As mentioned earlier, the 
therapeutic options and prognosis of mucosal ESCC (carcinoma in 
situ) is the same as high-grade ESD. Therefore, carcinoma in situ 
of the esophagus may also be considered as an appropriate target 
in secondary prevention of ESCC. Endoscopic therapeutic options 
including EMR result in complete elimination of these mucosal 
lesions and give a normal life with high quality to the patients.39 
   
Screening methods for ESCC
$VFUHHQLQJPHWKRGPLJKWKDYHSRWHQWLDOEHQH¿WIRUDGLVHDVHLI
the following assumptions are true about it. Firstly, the disease in 
all or most of cases starts from a detectable preclinical phase. Sec-
ondly, in the absence of intervention, most or all cases in preclini-
cal phase progress into clinical one.40 In case of ESCC, both of the 
above- mentioned assumptions are true.14 So, screening programs 
FDQEHHI¿FLHQWDQGKHOSIXOIRUFRQWUROOLQJ(6&&6HFRQGDU\SUH-
vention (to detect ESD and carcinoma in situ) has been consid-
ered as basic design in screening programs of ESCC. Endoscopy 
is the diagnostic choice for esophageal mucosal lesions.3,41 But it is 
an invasive and expensive method and especially is not accepted 
by asymptomatic cases.427KHUHIRUH LQYHVWLJDWRUV WULHG WR¿QGD
nonendoscopic screening method by considering a combination 
of various modalities such as cytologic examination and existence 
of various risk factors and molecular markers.43 Despite the large 
number of studies conducted throughout the world, no method has 
\HWEHHQDSSURYHGDVDQHI¿FLHQWQRQHQGRVFRSLF(6&&VFUHHQLQJ
test,3,44 and endoscopy remains as the best option for ESCC screen-
ing programs. A large number of studies have been conducted to 
develop the best endoscopic method for ESCC screening. We will 
Figure 1. Pathogenesis, etiology, and controlling methods of esophageal squamous cell 
carcinoma (ESCC).
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discuss about the details and results of these studies in the follow-
ing section of this paper.
Endoscopy with iodine staining
7KH¿UVWDQGPRVWLPSRUWDQWVWHSRI(6&&VFUHHQLQJSURJUDPVLV
to detect its premalignant lesions (ESD) as well as early-stage ma-
lignant lesions (carcinoma in situ). Endoscopy is considered as the 
method of choice for detecting these lesions and taking biopsy for 
KLVWRORJLFFRQ¿UPDWLRQ+RZHYHUWKHVHOHVLRQVDUHJHQHUDOO\LQ-
visible during conventional white-light endoscopic examination of 
HVRSKDJHDOOXPHQ6RLQYHVWLJDWRUVWULHGWR¿QGDPHWKRGWRPDNH
mucosal lesions visible through endoscopic examination. Schiller 
IRU WKH¿UVW WLPH LQWURGXFHGDPHWKRG WRKLJKOLJKWSUHPDOLJQDQW
lesions (squamous dysplasia) of the cervix. They considered io-
dine staining for early detection of mucosal abnormalities of the 
cervix.45 As epithelial cells of the cervix and esophagus are both of 
squamous cell type, a similar staining technique has been applied 
since the late 1960s to detect mucosal lesions of the esophagus.46–49
7KH VXSHU¿FLDO HSLWKHOLXP RI WKH QRUPDO VTXDPRXV HSLWKHOLD
(e.g., in the esophagus and cervix) contains abundant glycogen. 
Basically, iodine stains glycogen brown.50,51 So, if normal esopha-
geal epithelium is exposed to iodine, its color changes into dark 
brown. The glycogen content in abnormal mucosal lesion includ-
ing squamous dysplasia and carcinoma in situ is very low, and the 
areas with those lesions remain unstained, so called as unstained 
lesion in endoscopic examination.52,53 
Endoscopy with iodine (Lugol’s solution) staining of the esopha-
geal mucosa, so called as chromoendoscopy, has been used to de-
tect esophageal mucosal lesions and suggested to be considered in 
ESCC early detection (screening) programs in different popula-
tions. Mandard, et al. used iodine staining in 37 esophageal speci-
mens. They found normal esophageal mucosa as iodine-positive 
and invasive carcinoma and dysplastic lesions as iodine-negative 
]RQHV7KH\¿QDOO\VXJJHVWHGLRGLQHVWDLQLQJIRUHDUO\HQGRVFRSLF
diagnosis of EC.54 The usefulness of iodine staining to improve 
early detection of esophageal squamous neoplasia was reported by 
some investigators.55–63 
These studies were conducted on different high- risk populations. 
The results of a study from Brazil on patients with head and neck 
cancer, showed that Lugol chromoendoscopy diagnosed 100% 
of high-grade intraepithelial neoplasia while the detection rate 
by standard endoscopy was 55%.64 The results of other studies in 
similar high-risk populations also approved the validity of endos-
copy with iodine staining as an effective ESCC screening method 
in patients with head and neck cancers.65–69
Yokoyama, et al.70 conducted a screening program for early de-
tection of EC on a cohort of 629 high- risk individuals in Japan 
(alcoholic males) and concluded that chromoendoscopy is a useful 
method to detect dysplastic and neoplastic lesions of the esopha-
gus. Ban, et al. similarly showed the usefulness of endoscopy with 
iodine staining to detect early stages of EC in alcoholics.71 In a 
study from Brazil, Lugol chromoendoscopy was used to detect 
ESD in 190 high-risk asymptomatic males (those who consumed 
alcohol, cigarette, and mate) and ESDs were successfully detect-
ed.72 In a study on 225 healthy adults from a high EC-risk area in 
China, Dawsey, et al. found an increase, from 62% (before iodine 
staining) to 96% (after staining), in sensitivity of endoscopic ex-
amination for identifying high- grade ESD or ESCC.41 The results 
showed that 55% of moderate ESD and 23% of severe ESD were 
detected only after staining.
Chromoendoscopy was also reported to be useful in assessing 
the characteristics of esophageal mucosal lesions. It was reported 
to be effective in identifying margin lines of the lesions.73 Mori, et 
al. found that the thickness of the glycogen-containing cell layer 
ZDVZHOOLGHQWL¿HGE\VWDLQLQJLQWHQVLW\7KHLUUHVXOWVVKRZHGWKDW
Lugol test can be used for precise delineation of borders of the 
lesions.50 Kuwano, et al. similarly suggested endoscopic examina-
tion with Lugol staining as useful method to identify borders of 
early stages of EC.74 Dawsey, et al. also found a positive relation-
ship between size of unstained lesions and histologic diagnosis of 
the lesions (high-grade ESD or ESCC). They reported that the bor-
der of lesions in 88% of high-grade ESD and ESCC lesions were 
PRUHFOHDUO\GH¿QHG41
%HFDXVHRIWKHDERYHEHQH¿WVDQGLWVKLJKVHQVLWLYLW\DQGVSHFL-
¿FLW\FKURPRHQGRVFRS\KDVEHHQFRQVLGHUHGDVWKHJROGVWDQGDUG
method for diagnosis of abnormal esophageal mucosal lesions in 
different research projects.42,75 However, because of some limita-
tions, it may not be accepted at population level in some high-risk 
UHJLRQVLQFOXGLQJQRUWKHDVWHUQ,UDQ7KH¿UVWOLPLWDWLRQLVWKDWHQ-
doscopy is an invasive procedure. Its costs may be relatively high, 
especially in low-resources communities. In addition, the Lugol’s 
solution may cause complications including retrosternal pain and 
discomfort and even erosions or ulcers in the esophagus (due to 
mucosal irritation).76 
There is also another important limitation for this technique. The 
UHVXOWVRIVRPHVWXGLHVVXJJHVWHGWKDWWKHVSHFL¿FLW\RIFKURPRHQ-
doscopy for detecting ESD and early stages of ESCC was low. So, 
VRPHLQYHVWLJDWRUVWULHGWR¿QGDSSOLFDEOHPHWKRGVWRLPSURYHLWV
VSHFL¿FLW\,VKLKDUDHWDOFRQVLGHUHGWKHSDWWHUQRIFRORUFKDQJH
after iodine staining for this reason.77 After using Logol’s solu-
tion during endoscopic examination, the neoplastic lesions of the 
esophagus initially change into whitish yellow color and then pink 
two to three minutes later. This pattern is called as pink sign in 
chromoendoscopy. Using this sign, Ishihara, et al. reported an ac-
FHSWDEOHDFFXUDF\VHQVLWLYLW\ DQGVSHFL¿FLW\ IRU
chromoendoscopy to detect early stages of esophageal neoplasias. 
Further studies are warranted to determine if this technique is ap-
plicable for other high-risk areas. Anyway, modifying the standard 
chromoendoscopy may be helpful to develop a more applicable 
screening program for ESCC. Overall, considering chromoen-
doscopy for developing ESCC screening program should be in-
dividualized for each community. When cost-effectiveness and 
adherence of people, despite invasiveness of the procedure, are 
acceptable, chromoendoscopy may be used for population- level 
screening. Otherwise, nonendoscopic screening programs may be 
considered.44
Endoscopic tissue imaging without staining
+HUHZHEULHÀ\UHYLHZVRPHUHFHQWO\GHYHORSHGHQGRVFRSLFLP-
aging modalities that do not use staining. However, the validity 
of almost all of these methods in detecting ESD and early-stage 
ESCC is under question and needs further investigation. These 
methods are generally expensive and are not available in many 
populations, in particular low-resources countries in which most 
of high ESCC-risk areas are located.1 Therefore, these methods do 
not seem to be suitable for population-level screening programs in 
these populations.
Narrow-band imaging (NBI)
,Q1%,PHWKRGQDUURZEDQGZLGWK¿OWHUVLQDUHGJUHHQEOXHVH-
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(QGRVFRSLF6FUHHQLQJIRU(6&&
quential illumination system is used to enhance the accuracy of 
diagnosis.78 As a result, contrast between the epithelial surface and 
the vascular pattern is increased and different images will be pro-
duced at various levels of the mucosa, resulting in similar contrast 
enhancement when compared to Lugol chromoendoscopy.79 Add-
ing NBI to standard endoscopy was helpful in early detection of 
ESCC.80  Improvement in visualization of the intrapapillary capil-
lary loops was the main advantage of this technique.80 Different 
LQYHVWLJDWRUVUHSRUWHGKLJKVHQVLWLYLW\DQGVSHFL¿FLW\IRU1%,WR
detect neoplastic lesions in esophageal mucosa.81–83 Muto, et al. 
UHSRUWHGDVHQVLWLYLW\RIDQGDVSHFL¿FLW\RIIRU1%,
V\VWHP WRGHWHFW VHFRQGDU\ VXSHU¿FLDO(6&& OHVLRQV LQSDWLHQWV
with head and neck cancer. They suggested NBI as the standard 
method for screening ESCC in this high-risk population.84 
'LIIHUHQW¿QGLQJVPD\EHGHWHFWHG LQHVRSKDJHDOPXFRVDGXU-
LQJ1%,H[DPLQDWLRQ7KHGLDJQRVWLFYDOXHVRIWKHVH¿QGLQJVDUH
QRWWKHVDPH7KHVLJQL¿FDQFHRIGLIIHUHQW1%,¿QGLQJVZDVDV-
sessed by Ishihara, et al. They found that brownish epithelium and 
EURZQLVKGRWVDUHWKHPRVWLPSRUWDQW1%,¿QGLQJVWREHXVHGIRU
diagnosis of high-grade squamous neoplasia of the esophagus.85 
7KLV¿QGLQJQHHGVWREHLQYHVWLJDWHGLQODUJHUPXOWLFHQWHUVWXGLHV
to determine if it is applicable at population levels. There is another 
limitation for using NBI in primary care setting. Experience of en-
doscopist is an important issue for achieving successful results in 
NBI method. The results of a study from Japan showed that the 
sensitivity of NBI for detecting high-grade squamous neoplasia of 
WKHHVRSKDJXVZDVVLJQL¿FDQWO\KLJKHULQH[SHULHQFHGHQGRVFRSLVW
(100%) than less experienced endoscopist (69%).86
7KHEHQH¿WRIDFRPELQDWLRQRI1%,V\VWHPDQGPDJQLI\LQJHQ-
doscopy has been assessed in some studies. Yoshida, et al. reported 
more accurate assessment of esophageal lesions by considering 
such combination.87 Goda, et al.88 and Kawahara, et al.89 also sug-
gested that magnifying NBI endoscopy may be helpful for detect-
LQJDQGGLDJQRVLQJVXSHU¿FLDO(6&&
Confocal microscopy
 In this method, the standard endoscope is combined with mi-
FURVFRSHLPDJHSURFHVVLQJXQLW$GGLQJÀXRUHVFHQWDJHQWVDFUL-
ÀDYLQHK\GURFKORULGHRUÀXRUHVFHLQVRGLXPZLOOSURYLGHFHOOXODU
and histologic details of the tissue, resulting in detection of muco-
sal lesions.90 Liu, et al. used confocal laser endomicroscopy (CLE) 
WRGHWHFWVXSHU¿FLDO(6&&7KH\IRXQGWKDW&/(FDQVXFFHVVIXOO\
distinguish cancerous from normal epithelium and suggested it as 
a potential good method for early detection of EC.91 The poten-
WLDOSUREOHPZLWK WKLVV\VWHPLV WKHGLI¿FXOW\ LQREWDLQLQJJRRG
images. Further studies are needed to improve the validity of this 
method to detect mucosal lesions.
Endocytoscopy
 This method makes it possible to observe the cellular nuclei in 
the GI tract in vivo. Endocytoscoy system has been used to assess 
the characteristics of cells on the surface layer of early stages of 
ECs.92 By using this method it was possible to observe detailed 
histologic changes in esophageal lesions.93 Fujishiro, et al. report-
HGVLJQL¿FDQWGLIIHUHQFHLQFKDUDFWHULVWLFVRIHVRSKDJHDOHSLWKHOLDO
cells between cancerous and normal areas.94 They found close cor-
UHODWLRQEHWZHHQHQGRF\WRVFRSLFLPDJHVDQGKLVWRORJLF¿QGLQJRI
the esophageal biopsies. Evidences of neoplastic changes includ-
ing, increased cell density and nuclear abnormalities were reported 
in 84% of biopsy samples from ESCC cases.95
 Fluorescence endoscopy
,QWKLVPHWKRGUHDOWLPHÀXRUHVFHQFHLPDJHVDUHSURYLGHGE\
DGGLQJ ÀXRUHVFHQFH DJHQW WR VWDQGDUG HQGRVFRSH XVLQJ LPDJH
processing module.903ROJODVHHWDOVXFFHVVIXOO\XVHGDÀXRUHV-
cence confocal endomicroscope to assess GI tract. They showed 
that this new method may be considered to visualize the cellular 
and subcellular structures of squamous epithelium of the esopha-
gus and may be helpful to assess abnormal epithelial lesions of the 
esophagus.96 Uedo, et al. used a videoendoscopy system with auto-
ÀXRUHVFHQFHDQGUHÀHFWDQFHIRUHDUO\GHWHFWLRQRI(&V7KH\FRXOG
¿QGRIVXSHU¿FLDO(&VXVLQJWKLVPHWKRGDQGUHSRUWHGWKDW
their method had an advantage over standard videoendoscopy.97 
However, the accuracy of this method in another study, was less 
than chromoendoscopy and NBI.98
Trimodal imaging
 This technique consists of a combination of white-light endos-
FRS\DXWRÀXRUHVFHQFHDQG1%,6RPHVWXGLHVUHSRUWHGWKDWWKLV
method may improve the detection of Barrett’s dysplasia compared 
with standard endoscopy.99–101 It may be considered for early detec-
tion of ESCC premalignant and malignant lesion. Future studies 
are needed to assess validity of this technique to detect ESDs and 
early stages of ESCC.
Optical coherence tomography
In this method, low-coherence infrared light is used to produce a 
high-resolution image of the epithelium.90 It was used to diagnosis 
Barrett’s dysplasia in the esophagus.102 But its sensitivity was too 
low to be used in clinical setting.103 Further studies are warranted 
to assess the validity of this method to detect esophageal squamous 
lesions.
Elastic scattering spectroscopy
 This procedure is based on measurement of the epithelial elastic 
scattering index. This index may change as a result of alterations 
in cellular components (including nucleus and mitochondria) dur-
ing neoplastic process. It is measured by inserting an optical probe 
through the instrument channel of the endoscope. A high sensitivi-
ty was reported for this technique to detect dysplasia and neoplasia 
in Barrett’s esophagus.104 Future studies are needed to determine if 
this method is also helpful for early detection of ESCC.
Conclusion
Designing endoscopic ESCC screening program should be in-
dividualized for each population. Similar to all population-based 
screening programs, any screening for early detection of ESCC 
must be cost-effective; otherwise, screening may not be indicated 
in that population. Endoscopy with iodine staining has been ac-
cepted as a population-level ESCC screening program in some 
high-risk areas including parts of China. This method may be too 
expensive and invasive in other high-risk communities. Nonen-
doscopic methods may be more applicable in these populations 
for population-based screenings. The limitations (questionable 
validity and costs) of new endoscopic imaging modalities, includ-
ing NBI, made them inappropriate to be used in population-level 
ESCC screening programs. Low-cost, less-invasive endoscopic 
imaging methods with acceptable diagnostic performance may 
make screening of ESCC in high-risk areas cost-effective.
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